Artikel

Autologous stromal vascular fraction therapy for rheumatoid arthritis: rationale and clinical safety

---

Abstract
Advancements in rheumatoid arthritis (RA) treatment protocols and introduction of targeted biological therapiesb have markedly improved patient outcomes, despite this, up to 50% of patients still fail to achieve a significant clinical response. In veterinary medicine, stem cell therapy in the form of autologous stromal vascular fraction (SVF) is an accepted therapeutic modality for degenerative conditions with 80% improvement and no serious treatment associated adverse events reported. Clinical translation of SVF therapy relies on confirmation of veterinary findings in targeted patient populations. Here we describe the rationale and preclinical data supporting the use of autologous SVF in treatment of RA, as well as provide 1, 3, 6, and 13 month safety outcomes in 13 RA patients treated with this approach

---

Ketersediaan

Tidak ada salinan data

Informasi Detail

Judul Seri

-

No. Panggil

Artikel

Penerbit

USA : Springer., 2012

Deskripsi Fisik

-

Bahasa

English

ISBN/ISSN

doi:10.1186/1755-768

Klasifikasi

NONE

Tipe Isi

-

Tipe Media

-

Tipe Pembawa

-

Edisi

International Archives of Medicine 2012,5:5

Subjek

Medicine
vascular fraction therapy
rheumatoid arthritis
clinical safety

Info Detail Spesifik

-

Pernyataan Tanggungjawab

-

Versi lain/terkait

Lampiran Berkas

Komentar

---

Anda harus masuk sebelum memberikan komentar